Pharmaceutical News

RSS

Biopharmaceutical market generated revenues of USD 45.0 billion in 2004

New analysis from Frost & Sullivan, Strategic Analysis of the World Plant Molecular Farming Market, reveals that the biopharmaceutical market generated revenues of USD 45.0 billion in 2004. It is likely to reach USD 98.2 billion by 2011.

17 Jan 2005

FDA licenses Sanofi pasteur vaccine for protection against meningococcal disease

Sanofi pasteur, the vaccines business of the sanofi-aventis Group, announced today that the U.S. Food and Drug Administration (FDA) has licensed Menactra (Meningococcal [Groups A, C, Y and W-135] Polysaccharide Diphtheria Toxoid Conjugate Vaccine) for protection against meningococcal disease in adolescents and adults aged 11-55 years.

17 Jan 2005

Avastin available across Europe within the next few weeks

Roche has announced that the European Commission has approved Avastin (bevacizumab, rhuMAb-VEGF), the new innovative anti-angiogenesis drug, for the treatment of patients with previously untreated metastatic colorectal cancer.

16 Jan 2005

Committees will weigh up COX-2 benefits and risks

The U.S. Food and Drug Administration (FDA) has announced a joint public meeting of the agency's Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee to be held February 16, 17 and 18, 2005.

16 Jan 2005

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

Oncologists from USC/Norris Comprehensive Cancer Center are running tests on a new pancreatic cancer drug that targets the cancer from two directions.

13 Jan 2005

MHRA and FDA to inspect Chiron's Liverpool manufacturing facility

Chiron Corporation announced at a presentation at the 23rd Annual JPMorgan Healthcare Conference that the company anticipates that the UK Medicines and Healthcare products Regulatory Agency (MHRA), accompanied by U.S. Food and Drug Administration (FDA) inspectors as observers, will conduct a series of inspections of Chiron's Liverpool manufacturing facility.

13 Jan 2005

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Australian drug specialist Narhex Life Sciences, has announced a partnership with one of the world’s foremost US medical research centres to evaluate its protease inhibitor Nar DG 35 Prodrug for its activity against Hepatitis C and SARS viruses.

12 Jan 2005

Research breakthrough in treatment of TB and MDR-TB

FASgen Inc.'s compound, FAS20013, has emerged from an intense multi-year program of pre-clinical studies that clearly validate its potential as an ideal new drug for the treatment of tuberculosis and MDR-TB, the disease caused by organisms that are resistant to the drugs now commonly used to treat TB. Initial clinical trials in both TB and MDR-TB are scheduled for later this year.

12 Jan 2005

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Myriad Genetics announced today that it has initiated enrollment in a Phase 3 human clinical trial of its lead therapeutic candidate, Flurizan (MPC-7869), in patients with Alzheimer's disease.

12 Jan 2005

Amarin announces positive results from studies using Miraxion to treat unresponsive depression

Amarin Corporation today announced positive data analysis from two exploratory phase IIa clinical studies using Miraxion (formerly referred to as LAX-101c) to treat depression.

12 Jan 2005

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

With a 30 per cent revenue share, Europe trails the United States as the second largest regional market for therapeutic peptides. The rising need for new therapeutic approaches combined with the potential of peptides as active pharmaceutical ingredients for effective drug formulation is contributing to rapid market development.

12 Jan 2005

Safety established for Vaxin's first flu vaccine in clinical trial

Vaxin Inc., a privately-held biotechnology company, has demonstrated, in a Phase I human clinical study, that the company's recombinant influenza vaccine provides a potential alternative to traditional flu vaccines.

12 Jan 2005

Campral, first new treatment for alcoholism in ten years

Forest Laboratories announced that Campral (acamprosate calcium) Delayed- Release Tablets are now available to physicians, patients and pharmacies nationwide.

12 Jan 2005

Molecular Devices introduces fatty acid uptake assay to target metabolic diseases

Molecular Devices Corporation announced the launch of its QBT Fatty Acid Uptake Assay Kit, the first assay kit that addresses the need for a single-step, homogenous in vitro assay for fatty acid uptake for use in high- throughput screening and metabolic disease research.

12 Jan 2005

Potential new therapies for cancer and bleeding disorders

Lexicon Genetics announced today that it has advanced two of its drug discovery programs into preclinical development in preparation for investigational new drug (IND) applications.

10 Jan 2005

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Millennium Pharmaceuticals today announced, in collaboration with Johnson & Johnson Pharmaceutical Research & Development, LLC, the initiation of VISTA (Velcadeas Initial Standard Therapy in multiple myeloma: Assessment with melphalan and prednisone), a multicenter, international phase III clinical trial of Velcadein combination with melphalan and prednisone versus melphalan and prednisone in patients with newly diagnosed multiple myeloma (MM) who are not transplant candidates.

10 Jan 2005

Ranbaxy files anti-retrovirals (ARVs) to the U.S. FDA

Ranbaxy Laboratories Limited (Ranbaxy) announced today that the Company has so far made three filings of its Anti-Retrovirals (ARVs) to the U.S. FDA for its approval under the expedited review process of the President's Emergency Plan for AIDS Relief (PEPFAR).

10 Jan 2005

Pharmaceutical News

Biopharmaceutical market generated revenues of USD 45.0 billion in 2004

FDA licenses Sanofi pasteur vaccine for protection against meningococcal disease

Avastin available across Europe within the next few weeks

Committees will weigh up COX-2 benefits and risks

Evaluation of BAY 43-9006 (Sorafenib) for pancreatic cancer

MHRA and FDA to inspect Chiron's Liverpool manufacturing facility

Major partnership with National Institute of Allergy and Infectious Diseases for Narhex Life Sciences

Research breakthrough in treatment of TB and MDR-TB

Myriad Genetics initiates phase 3 clinical trial of Flurizan

Amarin announces positive results from studies using Miraxion to treat unresponsive depression

Escalating demand for novel and effective therapeutic approaches underlines growing appeal of peptides

Safety established for Vaxin's first flu vaccine in clinical trial

Campral, first new treatment for alcoholism in ten years

Molecular Devices introduces fatty acid uptake assay to target metabolic diseases

Potential new therapies for cancer and bleeding disorders

Velcade (bortezomib) phase III clinical trial initiated in patients with newly diagnosed multiple myeloma

Ranbaxy files anti-retrovirals (ARVs) to the U.S. FDA

Serono announces the availability of Saizen for adult growth hormone deficiency

Government should plough drug savings into Pharmaceutical Benefits Scheme (PBS)

Trial of naproxen and celecoxib suspended

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Latest News